ELQ-400

Networked: 2 relevant articles (0 outcomes, 0 trials/studies)

1.	Parasitemia 06/01/2015 - "Although cyt bc1 inhibitors are generally classified as slow-onset antimalarials, we found that a single dose of ELQ-400 rapidly induced stasis in blood-stage parasites, which was associated with a rapid reduction in parasitemia in vivo. "
2.	Toxoplasmosis 11/09/2018 - "Targeted Structure-Activity Analysis of Endochin-like Quinolones Reveals Potent Qi and Qo Site Inhibitors of Toxoplasma gondii and Plasmodium falciparum Cytochrome bc1 and Identifies ELQ-400 as a Remarkably Effective Compound against Acute Experimental Toxoplasmosis."
3.	Malaria 06/01/2015 - "Here, we describe a subset of cytochrome bc1 (cyt bc1) inhibitors, including the novel 4(1H)-quinolone ELQ-400, with single-dose activity against liver, blood, and transmission-stage parasites in mouse models of malaria. " 06/01/2015 - "Ultimately, ELQ-400 shows that cyt bc1 inhibitors can function as single-dose, blood-stage antimalarials and is the first compound to provide combined treatment, prophylaxis, and transmission blocking activity for malaria after a single oral administration. "

1.	Electron Transport Complex III (Coenzyme Q-Cytochrome-c Reductase)
2.	Quinolones
3.	Antimalarials (Antimalarial Agents)

1.	Oral Administration